AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03200392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser root surface conditioning & laser DGG harvesting
Description: laser root surface bio-modification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage
Study NCT03200392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser root surface conditioning & blade DGG harvesting
Description: laser root surface bio-modification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage
Study NCT03200392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blade DGG harvesting
Description: De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
Study NCT02139501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thrombopoietin (rhTPO)
Description: rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
Study NCT01219738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 360ug
Description: A single inhaled dose of 360ug budesonide from a DPI.
Study NCT01219738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 720ug
Description: A single inhaled dose of 720ug budesonide from a DPI.
Study NCT01578252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Tablets USP 8 mg
Description: 8 mg tablet once a day
Study NCT01578252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron Hydrochloride
Description: 8 mg tablet once a day
Study NCT01823237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study NCT01219738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 1440ug
Description: A single dose of 1440ug of the budesonide from DPI.
Study NCT01219738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide720ug 4 times
Description: 720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
Study NCT02214017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A videotelephone, TandBerg E20,
Study NCT01823237 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study NCT04591600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin and Doxycyline
Description: Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
Study NCT04591600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed
Study NCT04591600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed
Study NCT02107963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GD2-CAR engineered T cells
Description: Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg
Study NCT02107963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Description: If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity
Study NCT02107963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1800mg/m2/d X 2 days as a lymphodepleting regimen
Study NCT04164394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment (maltodextrin), once daily (u.i.d)
Study NCT04164394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: I31 Probiotic
Description: I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
Study NCT00660049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNaP Advanced Wound Care System
Description: Application of negative pressure device daily per instructions
Study NCT00660049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNaP
Description: Daily use
Study NCT00660049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNaP
Description: Daily application per protocol
Study NCT01649245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reiferon retard
Description: Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
Study NCT02795949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipseudomonal beta-lactam antibiotic
Description: Pharmaceutical form: solution for infusion
Study NCT02795949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: De-escalation(short-spectrum antibiotic)
Description: Pharmaceutical form: solution for infusion
Study NCT00484120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3%-Diclofenac-Nano-Emulsion Cream
Description: 3%-Diclofenac-Nano-Emulsion Cream
Study NCT00484120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream
Study NCT00937053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusion level 120 g/dL
Description: Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
Study NCT00937053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion level 70 g/dL
Description: Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
Study NCT00937053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Description: Patients whose platelets fall below 10 x 10\*9 will be transfused with platelets
Study NCT00937053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion
Description: Patients whose platelets fall below 10 x 10\*9 will be transfused with platelets
Study NCT01219738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single inhaled dose of placebo from a DPI.
Study NCT03361813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: trans-cutaneous ultrasound guided peritonsillar infiltration
Description: Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a transcutaneous route
Study NCT03361813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trans-oral ultrasound guided peritonsillar infiltration
Description: Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a trans-oral route
Study NCT00788723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
Study NCT00683904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL
Description: On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
Study NCT00683904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL
Description: After all participants in Dose Level 1 (ixabepilone, 32 mg/m\^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m\^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
Study NCT04283838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humanistic Care
Description: Psychological and physical rehabilitation based humanistic care regimen
Study NCT03392415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTO PCI
Description: attempted percutaneous coronary intervention of the chronic total coronary occlusion
Study NCT03392415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTO PCI
Description: attempted percutaneous coronary intervention of the chronic total coronary occlusion
Study NCT00949572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads
Description: 1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
Study NCT00949572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads
Description: 1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
Study NCT03349437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitabreath Device
Description: The VitaBreath device is designed for non-continuous use only and typical device use is expected to be for 2-3 minutes. The device should only be operated for less than 10 minutes at a time. After such time, the device should be turned off for at least 30 minutes
Study NCT02214017 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral motivation
Description: Optimization of medical care in diabetes
Study NCT03349437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pursed Lip Breathing
Description: Pursed lip breathing (PLB) is the standard of care and will be used as the control condition comparator.
Study NCT03951181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAP-MS
Description: The LEAP-MS intervention is a co-produced, digital interactive education and activity tool, specifically developed for PwPMS. The tool includes multimedia education about being active with PMS, tailored physical activity ideas and interactive functions enabling the development of personalised activity programmes, goal setting and activity logs. The digital tool works in conjunction with support from trained physiotherapists. The feasibility study will evaluate how the LEAP-MS intervention can be used in practice.
Study NCT04568642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activate FiO2 controller
Description: Closed-loop FiO2 controller will be activated in the experimental arm
Study NCT04568642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deactivate FiO2 controller
Description: Closed-loop FiO2 controller will be deactivated in the experimental arm
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alogliptin and Metformin FDC Placebo
Description: Alogliptin and metformin FDC placebo-matching tablets
Study NCT01050829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: Single administration at a dose of 0.1 mmol/kg
Study NCT01050829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadopentetate Dimeglumine (Magnevist, BAY86-4882)
Description: Single administration at a dose of 0.1 mmol/kg
Study NCT04121559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Interventions
Description: 1. Classroom lessons on nutrition, dietary diversity, healthy food choices and handwashing.~2. Principals provide messages on nutrition, dietary diversity, healthy food choices and handwashing at flag events or school assemblies.~3. Selected adolescent girls are mentored by science teachers as peer mentors and hold weekly group discussions with other girls to discuss nutrition, dietary diversity, healthy food choices and handwashing.~4. Trained science teachers take anthropometric measurements of adolescent girls to calculate BMI and provide nutrition counseling.~5. Parent-teacher meetings to inform and encourage parents about adolescent nutrition, dietary diversity, healthy snacks, and handwashing.
Study NCT04121559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Interventions
Description: 1. Home visits by HEWs and/or community volunteers to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing.~2. Community gatherings by HEWs and meetings with religious leaders to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing.
Study NCT04121559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School System Interventions
Description: 1. Workshop on the adolescent nutrition interventions for school principals, science teachers, HEWs, supervisors, and woreda officers.~2. Biweekly supportive supervision on adolescent nutrition activities for schools and HEWs by school supervisors or woreda health/education office.
Study NCT02214017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral motivation
Description: Optimization of medical care in diabetes
Study NCT01628783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg
Description: orally once daily
Study NCT01628783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT02301104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Study NCT02297945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metyrapone
Description: Single arm study
Study NCT03974308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive physiotherapy including balneotherapy and filling questionaire
Description: Three-week stay in a sanatorium with comprehensive physiotherapy including balneotherapy and three time filling questionaire.
Study NCT03974308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive physiotherapy without balneotherapy and filling questionaire
Description: Two-week outpatient treatment with comprehensive physiotherapy without balneotherapy and three time filling questionaire
Study NCT03974308 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention, only filling questionaire
Description: No physiotherapy nor balneotherapy applied but three time filling questionaire
Study NCT02865473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: topical instillation into the study eye
Study NCT04599673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMNIOGEN
Description: AmnioGen® amnion matrix allograft is a bioactive tissue matrix processed from 100% human amniotic tissue. The allograft is processed with advanced technology so the graft can be suspended in liquids and applied through needles and syringes.~Amniotic tissue is composed of structural extracellular matrix, which is rich in various types of collagen, growth factors, cytokines, and specialized proteins. Thus, the application of amniotic tissue is known to modulate localized tissue inflammation, reduce scar tissue formation and promote the healing of soft tissue.
Study NCT04599673 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 10 ml normal saline
Study NCT03743675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet-Induced Weight Loss
Description: Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.
Study NCT03743675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months.
Study NCT01055743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical resection
Description: Radical resection of hepatocellular carcinoma
Study NCT01055743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical resection
Description: Radical resection of hepatocellular carcinoma
Study NCT01055743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil Implants
Description: Implanted during the surgical treatment
Study NCT00856856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioabsorbable Everolimus Eluting Coronary Stent
Description: Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
Study NCT01891825 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical AF ablation
Description: Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
Study NCT01891825 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous AF ablation
Description: Percutaneous catheter ablation of atrial fibrillation
Study NCT03676894 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Fotona SP Dynamis
Description: Female patients with SUI will be treated with non-ablative Er:YAG laser with Fotona SP Dynamis with sham handpiece.
Study NCT03676894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravaginal Fotona SP Dynamis
Description: Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis
Study NCT03676894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravaginal Fotona SP Dynamis
Description: Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis
Study NCT03676894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraurethral Fotona SP Dynamis
Description: Female patients with SUI will be treated intraurethraly with non-ablative Er:YAG laser with Fotona SP Dynamis
Study NCT01318889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpanthenol
Description: 5% dexpanthenol Mouth wash , three times a day, 10 cc each time
Study NCT01921348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupressure pellets
Description: The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
Study NCT01921348 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupressure pellets
Description: The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
Study NCT02431975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network.